9th Cir. Says FDA May Regulate Stem Cell Treatment Under FDCA



DOCUMENTS
  • Order


SAN FRANCISCO – The 9th Circuit U.S. Court of Appeals has ruled that the FDA may regulate stem cell treatments, used for conditions such as osteoarthritis, because the mixture, known as stromal vascular fraction (SVF), is a “drug” under the Food, Drug and Cosmetic Act.

In a Sept. 27 opinion, the appellate panel reversed a California federal court’s judgment in favor of the defendants - doctors who create and administer SVF in clinics – whom the FDA accuses of violating the FDCA by improperly manufacturing and labeling the SVF product.

The panel further ruled that the FDA is authorized …

FIRM NAMES
  • Jones Day
  • Willkie Farr & Gallagher LLP





UPCOMING CONFERENCES




HarrisMartin’s Artificial Stone Silicosis Epidemic Litigation Conference

January 10, 2025 - Long Beach, CA
The Westin Long Beach

MORE DETAILS



HarrisMartin's MDL Conference

December 04, 2024 - New York, NY
Virgin Hotels NYC

MORE DETAILS